Bionano Genomics, INC DEF 14A proxy statements

Bionano Genomics has issued its 2026 proxy statement, outlining proposals for director elections, executive compensation, and auditor ratification.

Bionano Genomics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Bionano Genomics is asking stockholders to approve the issuance of shares upon exercise of warrants from a January 2025 securities purchase agreement to comply with Nasdaq listing rules.

Bionano Genomics is urging its stockholders to vote in favor of Proposal 2, a reverse stock split, to maintain its Nasdaq listing and improve its ability to raise capital.

Bionano Genomics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Bionano Genomics is holding a special meeting to seek shareholder approval for the issuance of shares related to warrants and a potential reverse stock split to maintain Nasdaq compliance.

Bionano Genomics has adjourned its Special Meeting of Stockholders to November 27, 2024, due to a lack of quorum and is urging stockholders to vote on the proposal to issue common stock upon the exercise of warrants.

Bionano Genomics adjourned its Special Meeting of Stockholders due to insufficient quorum and will reconvene on October 30, 2024, to allow additional time for stockholders to vote on a proposal regarding the issuance of common stock upon the exercise of warrants.

Bionano Genomics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Bionano Genomics is holding a special meeting of stockholders to approve the issuance of shares related to warrants issued in a July 2024 private placement, as required by Nasdaq listing rules.

Bionano Genomics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Bionano Genomics will hold its 2024 Annual Meeting of Stockholders virtually on June 18, 2024, to vote on director elections, executive compensation, and auditor ratification.